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Jung-Sun Kim, Hyuk-Jae Chang, Geu-Ru Hong, and Jong-Won Ha
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.
Purpose: We determined factors associated with long-term outcomes of patients who underwent successful percutaneous mitral 
balloon valvuloplasty (PMV). 
Materials and Methods: Between August 1980 and May 2013, 1187 patients underwent PMV at Severance Hospital, Seoul, Korea. 
A total of 742 patients who underwent regular clinic visits for more than 10 years were retrospectively analyzed. The endpoints 
consisted of repeated PMV, mitral valve (MV) surgery, and cardiovascular-related death.
Results: The optimal result, defined as a post-PMV mitral valve area (MVA) >1.5 cm2 and mitral regurgitation ≤Grade II, was ob-
tained in 631 (85%) patients. Over a mean follow up duration of 214±50 months, 54 (7.3%) patients underwent repeat PMV, 4 (0.5%) 
underwent trido-PMV, and 248 (33.4%) underwent MV surgery. A total of 33 patients (4.4%) had stroke, and 35 (4.7%) patients 
died from cardiovascular-related reasons. In a multivariate analysis, echocardiographic score [p=0.003, hazard ratio=1.56, 95% 
confidence interval (CI): 1.01−2.41] and post-MVA cut-off (p<0.001, relative risk=0.39, 95% CI: 0.37−0.69) were the only significant 
predictors of long-term clinical outcomes after adjusting for confounding variables. A post-MVA cut-off value of 1.76 cm2 showed 
satisfactory predictive power for poor long-term clinical outcomes.
Conclusion: In this long-term follow up study (up to 20 years), an echocardiographic score >8 and post-MVA ≤1.76 cm2 were in-
dependent predictors of poor long-term clinical outcomes after PMV, including MV reintervention, stroke, and cardiovascular-
related death.
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INTRODUCTION
Although the incidence of rheumatic valvular heart disease is 
decreasing in Korea, mitral stenosis (MS) is still an important 
cause of valvular heart disease. Percutaneous mitral balloon 
valvuloplasty (PMV) has become an effective and safe proce-
dure for symptomatic or hemodynamically significant MS 
with favorable valve anat omy since its first introduction.1-3 Re-
cent guidelines recommend PMV as the first therapeutic op-
tion for hemodynamically significant or symptomatic MS 
when mitral valve (MV) morphology favors PMV.4 While re-
cent studies have reported long-term (≥10 year) outcomes of 
PMV, these studies analyzed a predominantly Caucasian pop-
ulation.5-12 Although previous studies have shown that echo-
cardiographic scores based on valve morphology correlate with 
immediate clinical outcomes, these scores do not predict long-
term clinical outcomes.13 Thus, recent studies have focused on 
identifying long-term predictive factors, including hemody-
namic, clinical, and/or echocardiographic characteristics. 
However, most of these studies are based on predominantly 
Caucasian populations and have relatively limited follow up 
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durations (≤10 years).7,14 Moreover, Asian patients tend to be 
younger than those in Western countries; therefore, long-term 
clinical outcomes in Asian populations must be investigated as 
a distinct subgroup.
The aim of this study was to analyze the long-term results 
(≥20 years) of PMV at a single center. In addition, we deter-
mined the predictive factors of late clinical outcomes after suc-
cessful PMV.
MATERIALS AND METHODS
Study population
Between August 1980 and May 2013, 1187 patients underwent 
PMV at Severance Hospital, Seoul, Korea (Baseline characteris-
tics of 1187 patients are described at Supplementary Table 1, 
only online). Of these patients, we retrospectively analyzed 
those who had regular follow up visits for more than 10 years 
(n=742). Clinical status was determined by the New York Heart 
Assocation classification system. The indications of PMV were 
as follows: symptomatic moderate/severe MS with favorable 
valve morphology, asymptomatic moderate/severe MS with 
pulmonary hypertension and favorable valve morphology, 
and symptomatic moderate/severe MS with unfavorable valve 
morphology and unable/refused to undergo surgery. This 
study was approved by the Institutional Review Board of our in-
stitute (IRB No: 2013-2099-001).
Techniques
All procedures were performed via the anterograde transve-
nous approach by experienced physicians. The Inoue balloon 
technique or the double-balloon technique was used.15 The 
effective balloon-dilating area was calculated using standard 
geometric formulas and normalized to body surface area as pre-
viously described.16 The procedure was considered effective 
when full expansion of the balloon was accompanied by im-
provement in the mitral pressure gradient without detection 
of significant mitral regurgitation (MR) or any other mechani-
cal complication.16 Optimal PMV results were defined as mitral 
valve area (MVA) ≥1.5 cm2 with MR ≤GII/IV;1,3 suboptimal re-
sults were defined as MVA <1.5 cm2.2,14,17
Echocardiographic evaluation
Comprehensive 2-dimensional transthoracic echocardiogra-
hy (TTE) was performed in all patients before PMV and within 
48 hours after PMV. The total echocardiographic score was 
obtained as previously described by adding the scores of the 
following morphological features: leaflet mobility, thickness, 
calcification, and subvalvular lesions using Wilikins scores.13 
The MVA was measured by direct planimetry of the mitral ori-
fice in a 2-dimensional short axis view early in diastole and also 
by the pressure half-time method.18,19 Continous wave Doppler 
was used to calculate the mitral gradient and the peak pres-
sure gradient of tricuspid regurgitation (TR).15 
Follow up
Demographic, clinical, and procedural variables were collected 
retrospectively by medical record review and by telephone con-
tact. Clinical and echocardiographic assessments were car-
ried out 6 months after PMV. Event-free TTE was performed 
once every 3−5 years. Patients were followed up for a mean 
duration of 214±50 months after PMV. Restenosis was defined 
as MVA <1.5 cm2 from follow up TTE. Composite endpoints in-
cluded repeated MV intervention, stroke, or cardiovascular-
related death. Regarding repeated MV intervention, patients 
were analyzed with respect to whether they underwent any 
form of MV intervention, including redo PMV, trido PMV, or 
MV surgery. 
Statistical analysis
Continuous variables are expressed as mean±SD, and cate-
gorical variables are expressed as percentage. Chi-square 
analysis was used to compare continuous and categorical vari-
ables. Kaplan-Meier estimates were used to determine overall 
and event-free survival rates. Cox regression hazard analyses 
were used to identify independent correlates of long-term 
event-free survival. Additive predictive value was assessed by 
comparing the global chi-squre values. All analyses were per-
formed using SPSS software version 20 (IBM Corp., Armonk, 
NY, USA).
RESULTS
Baseline characteristics and immediate PMV 
outcomes
The baseline characteristics of the 742 patients are described 
in Table 1. The mean patient age was 41.2±11.1 years, and 75% 
of the patients were female. Optimal results (MVA ≥1.5 cm2 
and post MR ≤GII) were obtained in 631 (85%) patients. Post 
PMV MR >GII was documented in 58 (8%) patients. After PMV, 
the mean MVA increased significantly from 0.92 cm2 to 1.72 
cm2 (p<0.001), and the mean diastolic pressure gradient (MDPG) 
decreased from 9.63 mm Hg to 4.15 mm Hg (p<0.001). Severe 
MR requring surgery (repair or replacement) was performed 
in 6 (0.8%) patients, and pericardiocentesis was performed in 5 
(0.6%) due to cardiac tamponades. None had mitral annular 
rupture. 
The baseline characteristics of patients who achieved opti-
mal results differed significantly from those who achieved 
suboptimal results. Specifically, patients with optimal results 
were significantly younger and had sinus rhythm. Moreover, 
patients with optimal results had significantly lower echocar-
diographic score, larger pre MVA, smaller left atrium diameter, 
and less frequent significant TR (≥GII) (Fig. 1).
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Long-term clinical outcomes 
All 742 patients underwent regular follow up for more than 10 
years. Over a mean follow up duration of 214±50 months, 54 
(7.3%) patients undewent redo PMV, and 4 (0.5%) underwent 
trido-PMV. MV surgery was performed in 248 (33.4%) patients 
due to progression of MS, and mean time interval to MV sur-
gery was 126±72 months. A total of 33 patients (4.4%) experi-
enced stroke, and 35 (4.7%) patients died from cardiovascular-
related causes. The freedom from composite endpoint rates 
differed significantly between the optimal result group and 
suboptimal result group (p<0.001) (Fig. 2). The percentage of 
freedom from restenosis was 75% at 10 years and 53% at 15 
Table 1. Baseline Characteristics 
Variables Optimal (n=631) Suboptimal (n=111) p value
Clinical characteristics
Age (yr)   41±11   44±11 0.006
Women, n (%) 473 (75) 83 (75) 0.525
NYHA classification ≥III, n (%) 331 (53) 52 (43) 0.303
Atrial fibrillation, n (%) 238 (44) 66 (59) <0.001
Pre-OMC history, n (%) 28 (6) 7 (8) 0.473
Echocardiographic parameters
Echocardiographic score   7.8±1.2   8.4±1.4 <0.001
Echocardiographic score >8, n (%)   88 (14) 29 (26) 0.003
Pre-MVA, cm2 (2D planimetry)   0.94±0.31   0.81±0.38 <0.001
LV end diastolic dimension (mm) 48±8 50±8 0.066
LV end systolic dimension (mm) 36±8 38±9 0.054
Pre MDPG (mm Hg)   8.8±5.3   9.6±6.2 0.302
LV ejection fraction (%) 62±9   69±20 0.002
LAAP diameter (mm) 51±8   55±12 0.002
TR≥GII, n (%)   94 (15) 45 (41) <0.001
NYHA, New York Heart Association; OMC, open mitral commissurotomy; MVA, mitral valve area; 2D, two-dimensional; LV, left ventricle; MDPG, mean diastolic 
pressure gradient; LA, left atrium; AP, anterior-posterior; TR, tricuspid regurgitation.
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Fig. 1. Comparisons of pre-PMV echocardiographic score, MVA, LA AP diameter, and significant TR (≥GII) between patients with optimal and subopti-
mal PMV results. PMV, percutaneous mitral ballon valvuloplasty; MVA, mitral valve area;  LA, left atrium; AP, anterior-posterior; TR, tricuspid regurgitation.
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years. The event-free survival rate of the composite endpoints 
was 75% at 10 years and 43% at 15 years.
A univariate analysis indicated that age (p=0.041), pre-pro-
cedural atrial fibrillation (p<0.001), echocardiographic score 
>8 (p<0.001), post-MVA (p<0.001), post-MR ≥GII (p<0.001), and 
post-TR ≥GII (p<0.001) were associated with poor long-term 
clinical outcomes (Table 2). Multivariate analysis showed that 
echocardiographic score [p=0.003, hazard ratio=1.56, 95% 
confidence interval (CI): 1.01−2.41] and post-MVA (p<0.001, 
relative risk=0.39, 95% CI: 0.37−0.69) were significant predic-
tors of long-term clinical outcomes after adjusting for con-
founding variables. A post-MVA cut-off value of 1.76 cm2 
showed statistically significant predictive power for poor long-
term clinical outcomes [area under curve (AUC): 0.63, 95% CI: 
0.59−0.67, sensitivity: 66%, specificity: 56%, p<0.001]. Preoper-
ative clinical parameters (age, pre-atrial fibrillation), echocar-
diographic score >8, and post-MVA showed significant additive 
predictive value for poor long-term clinical outcomes (Fig. 3).
 
DISCUSSION
This study showed the long-term (up to 20 years) clinical out-
comes of patients who underwent PMV. An echocardiograph-
ic score >8 and post-MVA were significant predictors of poor 
long-term clinical outcomes. Up to now, only a few studies 
have reported long-term event-free survival rates. Previously 
reported 10-year event-free survival rates ranged from 61− 
88%,5,7,20 similar to our findings: Our result is in good agree-
ment with previous studies regarding satisfactory 10-year and 
15-year event-free survival rates. The rate of reintervention of 
MV, including redo/trido or MV surgery, over up to 20 years of 
follow up was 38%. 
We found that an echocardiographic score >8 and post-
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Fig. 2. Kaplan-Meier analysis of event-free survival rates for patients 
with optimal results after PMV and patients with suboptimal results af-
ter PMV. PMV, percutaneous mitral balloon valvuloplasty.
 Optimal group
 Suboptimal group
Table 2. Predictors of Long-Term Clinical Outcomes after Percutaneous Mitral Balloon Valvuloplasty.
Variables
Univariate Multivariate 
HR 95% CI p value HR 95% CI p value 
Age 1.02 1.01−1.03 0.041 1.01 0.99−1.02 0.303
Female 1.42 0.81−2.51 0.072 0.85 0.63−1.15 0.289
History of OMC 1.94 0.97−3.91 0.061
Atrial fibrillation 1.97 1.51−2.57 <0.001 1.58 0.94−1.61 0.144
Echocardiographic score >8 1.99 1.34−2.97 <0.001 1.56 1.01−2.41 0.003
Pre TR ≥GII 1.72 1.09−2.90 0.004 1.13 0.70−1.85 0.802
Pre MVA 0.99 0.69−1.42 0.972
Post MVA 0.51 0.37−0.69 <0.001 0.39 0.27− 0.57 <0.001 
Post MR ≥GII 1.78 1.00−2.01 <0.001 1.45 1.02−2.05 0.062
Post TR ≥GII 7.55 4.50−12.6 <0.001 7.03 0.58−1.71 0.989 
MR, mitral regurgitation; MVA, mitral valve area; OMC, open mitral commissurotomy; TR, tricuspid regurgitation.
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Fig. 3. Additive predictive value of echocardiographic score >8 and 
post-PMV mitral valve area (post-MVA) to baseline clinical parameters 
for predicting long-term clinical outcomes. *Age, atrial fibrillation. MVA, 
mitral valve area; PMV, percutaneous mitral balloon valvuloplasty.
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MVA were independent predictors of long-term clinical out-
comes after adjusting for confounding factors. In addition, they 
showed significant additive predictive value for predicting 
long-term clinical outcome in a consecutive manner. Favorable 
valve morphology, reflected by an echocardiographic score 
≤8, is known to be critical for optimal immediate results and 
event-free survival.13,21,22 Although patients with high echocar-
diographic score (>8) tend to have suboptimal results, howev-
er, others have suggested that suboptimal results are not nec-
essarily associated with poor long-term clinical outcomes.23 A 
few studies have suggested that long-term clinical outcomes 
are independent of echocardiographic scores.24,25 Our results 
showed that preprocedural echocardiographic score is an in-
dependent predictor of poor clinical outcomes after adjusting 
for confounding factors. Specifically, patients with suboptimal 
results had higher echocardiographic scores and showed sig-
nificantly poorer long-term clinical outcomes compared to pa-
tients with optimal results. 
Post-MVA was also an independent predictor of long-term 
clinical outcomes. In particular, post-MVA ≤1.76 cm2 showed 
statistically predictive value for predicting poor long-term clini-
cal outcomes (AUC: 0.63, 95% CI: 0.587−0.672, sensitivity: 66%, 
specificity: 56%, p<0.001). Among our cohort, 250 patients (34%) 
had post-MVA ≤1.76 cm2. However, discriminatory power was 
not very powerful. This finding is similar to those of previous 
mid-term follow-up studies. Song, et al.25 suggested that post-
MVA ≥1.9 cm2 was a good negative predictor for poor clinical 
outcomes with AUC value of 0.63 (sensitivity 72%, specificity 
58%, p<0.001). The modest discriminatory power of post-MVA 
for long-term clinical outcome after PMV could be explained 
by numerous other factors, such as commissural MR or atrial 
fibrillation.
Pre-MVA was not significantly associated with long-term 
clinical outcomes. Although patients with optimal results had 
significantly larger pre-MVA than those with suboptimal re-
sults, pre-MVA was not significantly associated with long-term 
clinical outcomes. However, younger patients (aged <50 years) 
with pre-MVA ≤1.0 cm2 had significantly worse event-free long-
term clinical outcomes (p=0.030) than those with pre-MVA 
1.0−1.5 cm2 (Supplementary Fig. 1, only online). This finding 
may reflect current trends of preferring PMV over MV surgery 
with mechanical valve, even with unfavorable valve morphol-
ogy, when MV intervention is indicated in younger patients.
Bouleti, et al.12 suggested that older patients (aged ≥50 
years) have significantly increased risk for surgery after PMV 
(57.3% vs. 32.3%, p<0.001). Our findings are consistent with 
these results. Specifically, the event-free survival rate was sig-
nificantly better in younger patients (aged <50 years) than 
older patients (aged ≥50 years, p<0.001). Although the univar-
iate analysis in the current study showed that age was a signif-
icant predictor (p=0.041) of long-term clinical outcomes, it was 
not, however, a significant predictor in the multivariate analysis. 
Some studies have also reported that significant post-MR 
(≥GII) is a strong predictor of event-free survival.26 However, 
we found that significant post-MR (≥GII) was not an indepen-
dent predictor of long-term clinical outcomes. Thus, severity 
alone does not reflect the influence of post-MR on long-term 
clinical outcomes after PMV. The mechanism of MR should be 
taken into consideration. After PMV, such mechanisms can be 
classified into commisural and non-commisural MR.27 Com-
misural MR is thought to be the most frequent type of MR af-
ter PMV. This type is caused by splits in fused commisures, 
which are often considered clinically not important.27 However, 
non-commisural MR is caused by subvalvular damage that 
leads to chordae rupture or leaflet tearing, which could result 
in poor prognosis.26 In fact, some studies have reported that 
the clinical outcomes of PMV differ depending on the mecha-
nism of post-MR.26,27 Kim, et al.26 demonstrated that non-com-
misural MR was a useful predictor for determining poor long-
term clinical outcomes (mean follow up >7 years) among 
patients with atrial fibrillation and higher MDPG. Unfortu-
nately, the retrospective nature of our study limited the assess-
ment of the mechanism of MR, which could explain non-sig-
nificant association between post-MR ≥GII and long-term 
clinical outcomes. 
Limitations
Because of the observational nature of the study, a cause-and-
effect relationship cannot be conclusively established be-
tween the predictors and the long-term outcomes. Moreover, 
these data were obtained from an Asian population at a single 
center, both of which should be considered in the interpreta-
tion of our data. Additionally, regular long-term follow up was 
not possible in all patients; therefore, the follow up TTE inter-
vals differed between the patients. Furthermore, since we in-
cluded only patients who had follow up data for more than 10 
years, those with poor compliance might have been excluded. 
Regarding echocargioraphic parameters, detailed informa-
tion on valvular calcification, the type of post-MR (commisural 
vs. non commisural) or 3D measurement of MVA could have 
yielded additional insight regarding predictors of long-term 
clinical outcomes. Further studies with novel echocardio-
graphic techniques could shed additional light on such pre-
dictors. 
Conclusion
This study reported long-term clinical outcomes after PMV in 
a large cohort of Asian individuals. In this long-term follow up 
study, an echocardiographic score >8 and post-MVA were in-
dependent predictors of poor long-term clinical outcomes after 
PMV, including MV reintervention, stroke, and cardiovascular-
related death. Post-MVA ≤1.76 cm2 showed satisfactory pre-
dictive value for predicting poor long-term clinical outcomes.
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